Hemab Therapeutics Holdings, Inc. (COAG) · Sep 24, 2026 · Exec change

Hemab adds Keli Walbert to board and audit committee without advancing pipeline

New audit director

Hemab strengthens board oversight with a new director, but the filing adds no clinical, financing, or regulatory catalyst.

Hemab is a clinical-stage biotech building a rare-bleeding-disorder pipeline around sutacimig, HMB-002, and earlier-stage HMB-003 programs. The filing adds governance capacity, not operating momentum. The board elected Keli Walbert effective immediately and placed her on the Audit Committee. 〔0〕 〔1〕 That may improve oversight as Hemab manages clinical development and public-company reporting, but it does not change a drug program, trial timeline, cash position, or regulatory path.

The economic impact is routine and modest relative to the company's development stage. Walbert receives $40,000 annually for board service plus $10,000 for Audit Committee work, along with a 36,000-share option that vests over three years. The option creates some dilution potential, but the filing provides no share-count context or indication that this is material to the broader financing story.

Bottom line: This is a new but routine governance addition. It modestly strengthens oversight while leaving Hemab's core clinical and funding narrative essentially untouched.

Original filing on SEC EDGAR

More Hemab Therapeutics Holdings, Inc. news

Hemab adds Keli Walbert to board and audit committee without advancing pipeline | COAG Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.